Eton Pharmaceuticals (ETON) to Post Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Eton Pharmaceuticals to post earnings of $0.13 per share and revenue of $27.1130 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The business had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. On average, analysts expect Eton Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Up 3.2%

Shares of NASDAQ:ETON opened at $48.13 on Thursday. The business has a 50-day moving average price of $35.42 and a 200 day moving average price of $26.11. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -687.47 and a beta of 0.86. Eton Pharmaceuticals has a 12-month low of $13.78 and a 12-month high of $50.18.

Analysts Set New Price Targets

A number of research firms have commented on ETON. Zacks Research cut shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Friday, July 17th. Finally, Canaccord Genuity Group began coverage on shares of Eton Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $60.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.50.

Insiders Place Their Bets

In related news, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the sale, the director owned 50,000 shares in the company, valued at approximately $1,624,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Krempa sold 19,679 shares of the stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the transaction, the insider directly owned 25,249 shares in the company, valued at approximately $794,586.03. The trade was a 43.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 150,000 shares of company stock valued at $4,853,921 over the last ninety days. Insiders own 16.49% of the company’s stock.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP acquired a new stake in shares of Eton Pharmaceuticals during the third quarter worth about $37,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $44,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the second quarter valued at approximately $41,000. New York State Common Retirement Fund acquired a new position in shares of Eton Pharmaceuticals in the second quarter valued at approximately $115,000. Finally, State of Wyoming increased its stake in Eton Pharmaceuticals by 50.0% during the 4th quarter. State of Wyoming now owns 8,161 shares of the company’s stock worth $138,000 after buying an additional 2,721 shares during the period. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.